马蔺子素与放疗合用治疗中晚期鼻咽癌疗效分析

Effect Analysis of Combined Irisiquinone and Radiotherapy for Middle and Late Stage Nasopharyngeal Cancer

目的：评价马蔺子素与放疗合用治疗鼻咽癌疗效。方法：用60Co－γ射线常规外照射，包括鼻咽部原发灶及颈部淋巴结转移灶原发灶DT 68Gy，颈转移灶或预防照射DT 40GyDT 60～72Gy，治疗组放疗前1天开始口服马蔺子素，110mg／次，2次／日，连用直至放疗结束。结果：半量疗效及全量（结束时）消失率：治疗组原发灶66．7％及96．7％，颈淋巴结转移灶69．2％及92．3％。对照组原发灶42．9％及71．4％，颈淋巴结转移灶48％及60％。半量疗效及全量消失率比较原发灶提高23．7％及26．4％，转移灶提高21．2％及32．3％。结论：马蔺子素与放疗合用治疗鼻咽癌两组有显著差异（P＜0．05），提示马蔺子素有放射增敏作用。

Objective To evaluate the radiosensitizing effect of Irisquinone combined with radiotherapy． Methods Out－irradiation of 60Co－γ including primary nasopharyngeal cancer PNC.DT 68Gy.cervical metastatic lymph nodes DT 60～72Gy or preventive irradiation DT40Gy were used． Irisquinone 110mg qd or bid orally was given one day prior to the radiotherapy and it was continued until the end of irradiation． Results In the treatment group.the PR and CR of PNC were 66．6％.97．7％.and those of metastatic cervical nodes were 69．2％.91．3％.while in the control group.PR and CR of PNC and metastatic cervical nodes were 42．9％.71．3％ and 48％.60％ respectively． In comparison.the PR and CR of the treatment group were higher than those in the control group． Conclusion The result showed that Irisqinone has significant radiosensitizing effects on nasopharyngeal cancer．